Recurrent C. difficile: Can a Vancomycin Taper Help?

How does C. difficile relate to antibiotic use during COVID-19?

CDC's review of COVID-19 and antimicrobial resistance documents extensive antibiotic exposure during the pandemic: almost 80% of patients hospitalized with COVID-19 received antibiotics between March and October 2020. These medicines do not treat SARS-CoV-2, although they can be necessary when a bacterial infection accompanies the viral illness. Those figures describe an earlier pandemic period, rather than current prescribing rates. [CDC pandemic review](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

C. difficile illustrates a related consequence of antibiotic exposure. Antibiotics can disturb the protective community of microbes in the intestine, allowing this bacterium to cause diarrhea and inflammation of the colon. CDC includes C. difficile alongside resistant infections in its reporting while explaining that it is not typically resistant to antibiotics. The distinction matters: preventing antibiotic-associated illness requires attention to the effects of treatment as well as whether a drug can kill a pathogen. [CDC information on C. difficile](https://www.cdc.gov/c-diff/about/).

What did the vancomycin taper trial find?

The double-blind OpTION trial, published July 28, 2026, studied first or second recurrences. It compared 10-day courses of vancomycin or fidaxomicin with vancomycin followed by a three-week taper and pulse. Symptom resolution without subsequent diarrhea through day 59 occurred in 58.6% of the taper group and 44.1% of each comparison group.

However, the taper comparison's P value of 0.04 missed the prespecified significance threshold of 0.0255. The numerical advantage therefore remains uncertain; the authors proposed a larger trial. These results also do not prove the treatments equivalent. [OpTION trial in NEJM Evidence](https://evidence.nejm.org/doi/full/10.1056/EVIDoa2600016).

How should clinicians choose treatment for recurrent C. difficile?

The 2021 IDSA/SHEA focused guideline conditionally favors fidaxomicin over a standard vancomycin course for recurrent infection, with low certainty of evidence. It also recognizes tapered and pulsed vancomycin as an acceptable option for a first recurrence. Tapering means progressively reducing treatment frequency; pulsing introduces intervals between doses. This is a prescribed regimen requiring clear instructions. [IDSA/SHEA treatment guideline](https://www.idsociety.org/practice-guideline/clostridioides-difficile-2021-focused-update/).

Diagnosis remains essential before another antibiotic course. CDC distinguishes symptomatic infection from colonization, in which a person carries C. difficile without illness. A positive test alone does not establish that the bacterium explains a patient's symptoms. Clinicians should also review antibiotics prescribed for other conditions and determine whether they remain necessary. When symptoms resolve, routine testing to confirm clearance is discouraged because patients can remain colonized. [CDC clinical overview](https://www.cdc.gov/c-diff/hcp/clinical-overview/).

For patients, the practical priority is a treatment plan that includes follow-up if diarrhea returns. Diarrhea during or after antibiotics warrants clinical assessment, but it has several possible causes. Severe abdominal pain or dehydration requires prompt medical attention. [CDC symptoms and treatment guidance](https://www.cdc.gov/c-diff/about/).